General Information

Dezocine Impurities and Dezocine

Daicel Pharma synthesizes Dezocine impurities of exceptional quality, such as (5R,11S,13R)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol and (5R,11S,13R)-3-methoxy-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-13-amine. These impurities are crucial to assess the purity, reliability, and safety of an active pharmaceutical ingredient, Dezocine. Besides, Daicel Pharma provides custom synthesis of Dezocine impurities to meet clients’ demands for delivery worldwide.

Dezocine [CAS: 53648-55-8], a synthetic opioid analgesic, exhibits a combination of opioid agonist and antagonist properties. While it is for pain management, its administration to individuals already dependent on other opioids can result in an opioid withdrawal syndrome.

Dezocine: Use and Commercial Availability  

Dezocine, available under the brand, Dalgan, treats moderate to severe pain. It belongs to the class of partial agonist opioids, with buprenorphine, which has a limited role in managing cancer pain due to the ceiling effect for analgesia. Structurally, Dezocine is a bridged aminotetralin, sharing similarities with other opioid agonist/antagonist drugs like pentazocine and butorphanol. As a result, it interacts with similar targets within the body. Dezocine’s analgesic and somnolent effects are dose-dependent, indicating its action on the kappa-opioid receptor.

Dezocine Structure and Mechanism of Action

The chemical name of Dezocine is (5R,11S,13S)-13-Amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-5,11-methanobenzocyclodecen-3-ol. Its chemical formula is C₁₆H₂₃NO, and its molecular weight is approximately 245.36 g/mol.

Dezocine binds to various opiate receptors.

Dezocine Impurities and Synthesis

During the synthesis¹ of Dezocine, impurities form as byproducts or reaction intermediates. They can arise from the starting materials, reagents, or reaction conditions used in manufacturing. It is necessary to identify and characterize them to ensure the purity and safety of the final Dezocine product. Analytical techniques such as chromatography and spectroscopy help in impurity profiling and quantification. Manufacturers employ strict quality control measures to minimize impurities and adhere to regulatory guidelines, ensuring the production of high-quality Dezocine for therapeutic use.

Daicel Pharma offers a Certificate of Analysis (CoA) for Dezocine impurity standards, such as (5R,11S,13R)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol and (5R,11S,13R)-3-methoxy-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-13-amine, generated from an analytical facility compliant with cGMP standards. The CoA includes a comprehensive characterization report comprising data from techniques like 1H NMR, 13C NMR, IR, MASS, and HPLC purity. Furthermore, on request, we give additional data like 13C-DEPT and CHN. Daicel Pharma can synthesize unknown Dezocine impurities or degradation products. A complete characterization report accompanies every delivery.